These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2591943)

  • 1. Oral contraceptive use influences resting breast proliferation.
    Anderson TJ; Battersby S; King RJ; McPherson K; Going JJ
    Hum Pathol; 1989 Dec; 20(12):1139-44. PubMed ID: 2591943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of menstrual cycle, parity and oral contraceptive use on steroid hormone receptors in normal breast.
    Battersby S; Robertson BJ; Anderson TJ; King RJ; McPherson K
    Br J Cancer; 1992 Apr; 65(4):601-7. PubMed ID: 1562470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for pathologically confirmed benign breast disease.
    Parazzini F; La Vecchia C; Franceschi S; Decarli A; Gallus G; Regallo M; Liberati A; Tognoni G
    Am J Epidemiol; 1984 Jul; 120(1):115-22. PubMed ID: 6741913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer among young U.S. women in relation to oral contraceptive use.
    White E; Malone KE; Weiss NS; Daling JR
    J Natl Cancer Inst; 1994 Apr; 86(7):505-14. PubMed ID: 8133534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast.
    Williams G; Anderson E; Howell A; Watson R; Coyne J; Roberts SA; Potten CS
    Int J Cancer; 1991 May; 48(2):206-10. PubMed ID: 2019467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A study on the association between the use of oral contraception and cancer of the breast or cervix: preliminary findings of a French study].
    Le MG; Bachelot A; Doyen F; Kramar A
    Contracept Fertil Sex (Paris); 1985 Mar; 13(3):553-8. PubMed ID: 12280145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell turnover in the "resting" human breast: influence of parity, contraceptive pill, age and laterality.
    Anderson TJ; Ferguson DJ; Raab GM
    Br J Cancer; 1982 Sep; 46(3):376-82. PubMed ID: 7126427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.
    Pike MC; Henderson BE; Krailo MD; Duke A; Roy S
    Lancet; 1983 Oct; 2(8356):926-30. PubMed ID: 6138501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for breast cancer in women undergoing mammography.
    Reuter KL; Baker SP; Krolikowski FJ
    AJR Am J Roentgenol; 1992 Feb; 158(2):273-8. PubMed ID: 1729780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
    Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
    Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of reproductive factors and use of oral contraceptives in the aetiology of breast cancer in women aged 50 to 74 years.
    Magnusson CM; Persson IR; Baron JA; Ekbom A; Bergström R; Adami HO
    Int J Cancer; 1999 Jan; 80(2):231-6. PubMed ID: 9935204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
    Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
    J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The present state of research on the relationship of oral contraceptives to breast cancer].
    Pike MC
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):329-38. PubMed ID: 12280203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles.
    Going JJ; Anderson TJ; Battersby S; MacIntyre CC
    Am J Pathol; 1988 Jan; 130(1):193-204. PubMed ID: 3337211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptive use and breast cancer risk: a meta-analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use.
    Rushton L; Jones DR
    Br J Obstet Gynaecol; 1992 Mar; 99(3):239-46. PubMed ID: 1534994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of oral contraceptive use.
    Williams RS
    Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IPPF statement on oral contraceptives and cancer of the breast.
    International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
    IPPF Med Bull; 1989 Apr; 23(2):4. PubMed ID: 12342374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproductive and hormonal factors and breast cancer in a Northern Italian population.
    Talamini R; La Vecchia C; Franceschi S; Colombo F; Decarli A; Grattoni E; Grigoletto E; Tognoni G
    Int J Epidemiol; 1985 Mar; 14(1):70-4. PubMed ID: 3988443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
    Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
    Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.